An Open-label, Single-arm, Multi-centre, Long-term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Clinical Trials
Principal Investigator
Sunil KaliaOverview
Study Start/End
Mar 28, 2019 to Jul 31, 2019Locations
Vancouver General HospitalPhone
604-875-5296Purpose of Study
The purpose of this extension trial is to evaluate the long-term safety of tralokinumab in patients with atopic dermatitis.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.